Amy Mao focuses her practice on the representation of both issuers and underwriters on a broad range of capital markets transactions, including initial public offerings and other public and private equity offerings, as well as high-yield, investment-grade and convertible debt issuances. Amy also regularly advises clients on general corporate matters, including SEC reporting and corporate governance.

Download full bio 

Experience

  • Erasca – $345 Million IPO 

  • Singular Genomics Systems – $258 Million IPO 

  • Vocera Communications – $200 Million Convertible Notes Offering 

  • Angion Biomedica – $92 Million IPO 

Education

  • Columbia Law School
    JD, 2017

  • UC San Diego
    BS, Biochemistry
    cum laude, 2013


Admissions & Credentials

New York

Not admitted to practice in California